[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100620074":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":12,"centralContacts":22,"locations":27,"responsibleParty":78,"collaborators":82,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":93,"eligibilityCriteria":94,"healthyVolunteers":89,"sex":95,"minAge":96,"maxAge":12,"enrollmentInfo":97,"targetDuration":12,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":12,"overallStatus":30,"whyStopped":12,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Beijing Anzhen Hospital","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Usual Care","NO_INTERVENTION","Usual Care with guideline-recommended outpatient follow-up. No platform-based risk stratification or decision support is provided.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Digital Remote Management","EXPERIMENTAL","Participants will use a digital remote-management platform to report symptoms and key physiologic variables (e.g., blood pressure and body weight). The platform applies a predefined risk-stratification algorithm and provides clinician-facing decision support for GDMT titration and congestion management. A comprehensive management for core health metrics will also be provided. Clinicians review and confirm recommendations before they are communicated to patients.",[18],"Other: Digital Remote Management",[20],{"type":6,"name":14,"description":16,"armGroupLabels":21,"otherNames":12},[14],[23],{"name":24,"role":25,"phone":26,"phoneExt":12,"email":26},"DigiCare-HFrEF Coordinating Center","CONTACT","chshma@vip.sina.com",[28,40,45,53,61,70],{"facility":29,"status":30,"city":31,"state":12,"zip":12,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":12},"Beijing Anzhen Hospital, Capital Medical University, Beijing, China","RECRUITING","Beijing","China","CN",{"type":35,"coordinates":36},"Point",[37,38],116.39723,39.9075,{"lat":38,"lon":37},{"facility":41,"status":30,"city":31,"state":12,"zip":12,"country":32,"countryCode":33,"cosmosGeoPoint":42,"geoPoint":44,"contacts":12},"Beijing Tongren Hospital, Capital Medical University, Beijing, China",{"type":35,"coordinates":43},[37,38],{"lat":38,"lon":37},{"facility":46,"status":30,"city":47,"state":12,"zip":12,"country":32,"countryCode":33,"cosmosGeoPoint":48,"geoPoint":52,"contacts":12},"The First Affiliated Hospital of Dalian Medical University, Dalian, China","Dalian",{"type":35,"coordinates":49},[50,51],121.60222,38.91222,{"lat":51,"lon":50},{"facility":54,"status":30,"city":55,"state":12,"zip":12,"country":32,"countryCode":33,"cosmosGeoPoint":56,"geoPoint":60,"contacts":12},"The First Hospital of Jilin University, Changchun, China","Jilin City",{"type":35,"coordinates":57},[58,59],126.5608,43.84652,{"lat":59,"lon":58},{"facility":62,"status":63,"city":64,"state":12,"zip":12,"country":32,"countryCode":33,"cosmosGeoPoint":65,"geoPoint":69,"contacts":12},"The Second Affiliated Hospital of Nanchang University, Nanchang, China","NOT_YET_RECRUITING","Nanchang",{"type":35,"coordinates":66},[67,68],115.85306,28.68396,{"lat":68,"lon":67},{"facility":71,"status":63,"city":72,"state":12,"zip":12,"country":32,"countryCode":33,"cosmosGeoPoint":73,"geoPoint":77,"contacts":12},"Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China","Shanghai",{"type":35,"coordinates":74},[75,76],121.45806,31.22222,{"lat":76,"lon":75},{"type":79,"investigatorFullName":80,"investigatorTitle":81,"investigatorAffiliation":5,"oldNameTitle":12,"oldOrganization":12},"PRINCIPAL_INVESTIGATOR","Chang sheng Ma","Director of cardiology department",[83,85],{"name":84,"class":6},"The First Hospital of Jilin University",{"name":86,"class":6},"Second Affiliated Hospital of Nanchang University","100620074","digital-remote-management-versus-usual-care-for-optimization-of-guideline-directed-medical-therapy-in-patients-with-heart-failure-and-reduced-ejection-fraction-a-multicentre-randomised-controlled-trial-digicare-hfref-100620074",false,"NCT07352891","Digital Remote Management Versus Usual Care for Optimization of Guideline-directed Medical Therapy in Patients With Heart Failure and Reduced Ejection Fraction: a Multicentre, Randomised, Controlled Trial (DigiCare-HFrEF)","Digital Remote Management for Care and Continuous Optimization Versus Usual Care for Optimization of Guideline-directed Medical Therapy in Patients With Heart Failure and Reduced Ejection Fraction (DigiCare-HFrEF): a Multicentre, Randomised, Controlled Trial","DigiCare-HFrEF","Inclusion Criteria:\n\n1. Adults aged ≥18 years.\n2. Hospitalised at a secondary or tertiary hospital with established heart failure care capacity.\n3. Diagnosed with HFrEF within the past 3 months according to the 2022 ACC\u002FAHA\u002FHFSA guideline diagnostic pathway, including: LVEF ≤40% by echocardiography; typical heart-failure symptoms and\u002For signs; and exclusion of non-HF causes of symptoms.\n4. Not optimized on guideline-directed medical therapy (GDMT) at enrollment, defined as at least two of the following four foundational drug classes not initiated or administered at \\\u003C50% target dose.\n5. Written informed consent provided.\n\nExclusion Criteria:\n\n1. Absolute contraindication to heart failure pharmacotherapy.\n2. History of heart transplantation or currently on a transplant waiting list.\n3. Receiving or planning implantation of a left ventricular assist device.\n4. Pregnant or breastfeeding women.\n5. Organ transplantation within the past 12 months.\n6. Unable to use the remote management platform as required (e.g., cognitive impairment or lack of caregiver support).\n7. Unable to perform blood pressure or body-weight monitoring (e.g., severe limb disability).\n8. Unable to express willingness or comply with follow-up requirements (e.g., unable to use internet-enabled devices).\n9. Any other condition judged by the investigator to make the patient unsuitable for participation.","ALL","18 Years",{"count":98,"type":99},252,"ESTIMATED","INTERVENTIONAL",[102],"NA","DigiCare-HFrEF is an investigator-initiated, multicentre, randomised, open-label, endpoint-blinded, superiority trial designed to evaluate whether a structured digital remote-management platform can optimise guideline-directed medical therapy (GDMT) in patients with heart failure with reduced ejection fraction (HFrEF) after hospital discharge. Eligible adults (≥18 years) with a confirmed diagnosis of HFrEF within the past 3 months (left ventricular ejection fraction ≤40%) who are not optimally treated with GDMT-defined as at least two of the four foundational drug classes (ACEi\u002FARB or ARNi, β-blocker, MRA, SGLT2 inhibitor) either not initiated or prescribed at \\\u003C50% of the target dose-will be randomly assigned in a 1:1 ratio to digital remote management or usual care. In the intervention arm, patients will report symptoms and key physiologic measures (e.g., blood pressure, heart rate, and body weight) via the platform; an algorithm will perform risk stratification and generate GDMT optimisation suggestions and decongestion prompts, as well as a comprehensive management for core health metrics, which are reviewed and confirmed by clinicians before implementation. The primary endpoint is the change in GDMT score from baseline to 3 months (ΔGDMT).",[105],"Heart Failure With Reduced Ejection Fraction","2026-04-21",{"date":108,"type":109},"2026-04-24","ACTUAL",{"date":111,"type":109},"2026-02-26",{"date":113,"type":99},"2026-07",{"name":5,"class":6},6]